Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Biogenomics
Deal Size : Undisclosed
Deal Type : Partnership
USV, Biogenomics Launch Biosimilar Insulin Aspart INSUQUICK
Details : Under the partnership, USV and Biogenomics launched Insuquick, India's first biosimilar insulin aspart, a rapid-acting analogue of insulin, for the treatment of diabetes.
Brand Name : Insuquick
Molecule Type : Peptide
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Biogenomics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EMA CHMP Recommends Grant of Marketing Authorization of Insulin Aspart Biosimilars
Details : Truvelog Mix 30 is approved and available as a 100 U/ml suspension for injection. The active substance of Truvelog Mix 30 is insulin aspart, an intermediate- or long-acting insulin which is combined with fast-acting insulin and used in diabetes.
Brand Name : Truvelog Mix 30
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 24, 2022
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
At278 Insulin Shows Superiority in Phase I Trial for Type 2 Diabetes
Details : AT278 is an ultra-concentrated, ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection. It is being evaluated for the treatment of type 2 diabetics.
Brand Name : AT278
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 20, 2024
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
Details : Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Meitheal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arecor Granted Key U.S. Patent Protecting Proprietary Insulin Products
Details : AT247 is an ultra-rapid insulin that aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes.
Brand Name : AT247
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 23, 2022
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).
Brand Name : GL-ASP
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 02, 2021
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Kixelle, a fast-acting insulin analog indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above, has been approved as a 100 units/ml solution for injection in vial and pre-filled pen presentations.
Brand Name : Kixelle
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 12, 2021
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Lannett
Deal Size : Undisclosed
Deal Type : Collaboration
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
Details : The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
February 09, 2021
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Lannett
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
